Sequenta sales and marketing update

Sequenta launched ClonoSIGHT in the U.S. to detect residual disease in patients with acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Sequenta of...